Amazon coin set to soar 25X – starting December 16th?

This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team of crypto experts has identified it as the most promising crypto of 2024. You can see all of the details surrounding the #1 Crypto of 2024

Christopher Heery net worth and biography

Christopher Heery Biography and Net Worth

Chief Medical Officer of Arcellx

Chris has served as Arcellx’s Chief Medical Officer since April 2021. Prior to that, he served as Chief Medical Officer of Precision BioSciences and Bavarian Nordic. At Precision, he oversaw the clinical development of one of the first allogeneic CAR-T cell platforms and provided clinical insight into clinical efforts for gene editing therapeutics. While at Bavarian Nordic, he oversaw clinical development programs for its immune-oncology and infectious disease vaccine portfolio. Prior to his roles in biotech, he was head of the Clinical Trials Group of the Laboratory of Tumor Immunology and Biology at the National Cancer Institute (NCI). He joined NCI Medical Oncology Branch as a Medical Oncology Fellow in 2009 and held an Adjunct Appointment in the Genitourinary Malignancies Branch. At NCI, Dr. Heery was part of the larger effort of the Laboratory of Tumor Immunology and Biology to create new immunotherapies for the treatment of cancer. Dr. Heery is board-certified in Medical Oncology and Internal Medicine and completed his internal medicine residency at the University of Illinois at Chicago after receiving his MD from East Carolina University Brody School of Medicine. Dr. Heery also holds a BA in English Literature from Duke University.

What is Christopher Heery's net worth?: The estimated net worth of Christopher Heery is at least $700,860.12 as of September 5th, 2024. Dr. Heery owns 9,278 shares of Arcellx stock worth more than $700,860 as of December 21st. This net worth estimate does not reflect any other investments that Dr. Heery may own. Additionally, Dr. Heery receives a salary of $683,400.00 as Chief Medical Officer at Arcellx. Learn More about Christopher Heery's net worth.
How old is Christopher Heery?: Dr. Heery is currently 44 years old. There are 5 older executives and no younger executives at Arcellx. The oldest executive at Arcellx is Mr. David Tice Ph.D., Chief Scientific Officer, who is 53 years old. Learn More on Christopher Heery's age.
What is Christopher Heery's salary?: As the Chief Medical Officer of Arcellx, Inc., Dr. Heery earns $683,400.00 per year. The highest earning executive at Arcellx is Mr. Rami Elghandour, Chairman and Chief Executive Officer, who commands a salary of $941,670.00 per year. Learn More on Christopher Heery's salary.
How do I contact Christopher Heery?: The corporate mailing address for Dr. Heery and other Arcellx executives is , , . Arcellx can also be reached via phone at 240-327-0603 and via email at [email protected]. Learn More on Christopher Heery's contact information.
Has Christopher Heery been buying or selling shares of Arcellx?: Christopher Heery has not been actively trading shares of Arcellx during the past quarter. Most recently, Christopher Heery sold 3,421 shares of the business's stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $70.02, for a transaction totalling $239,538.42. Following the completion of the sale, the insider now directly owns 9,278 shares of the company's stock, valued at $649,645.56. Learn More on Christopher Heery's trading history.
Who are Arcellx's active insiders?: Arcellx's insider roster includes Jill Carroll (Director), Rami Elghandour (Chairman and Chief Executive Officer), Michelle Gilson (CFO), Christopher Heery (Chief Medical Officer), Kavita Patel (Director), Olivia Ware (Director), and Olivia Ware (Director). Learn More on Arcellx's active insiders.
Are insiders buying or selling shares of Arcellx?: In the last year, insiders at the sold shares 30 times. They sold a total of 853,721 shares worth more than $59,734,002.56. The most recent insider tranaction occured on December, 3rd when Director Kavita Patel sold 1,500 shares worth more than $137,820.00. Insiders at Arcellx own 6.2% of the company. Learn More about insider trades at Arcellx.
Information on this page was last updated on 12/3/2024.

Christopher Heery Insider Trading History at Arcellx

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/5/2024	Sell	3,421	$70.02	$239,538.42	9,278
9/3/2024	Sell	27,451	$67.03	$1,840,040.53	9,278
8/26/2024	Sell	21,684	$71.12	$1,542,166.08	9,278
7/16/2024	Sell	10,901	$65.30	$711,835.30	9,278
7/11/2024	Sell	3,671	$60.01	$220,296.71	9,278
7/1/2024	Sell	20,000	$55.39	$1,107,800.00	9,278
6/12/2024	Sell	20,000	$55.13	$1,102,600.00	9,278
5/1/2024	Sell	18,168	$51.33	$932,563.44	8,938
3/26/2024	Sell	5,450	$69.11	$376,649.50	8,938
3/22/2024	Sell	41,365	$70.18	$2,902,995.70	8,938
2/12/2024	Sell	2,967	$64.46	$191,252.82	30,303
2/8/2024	Sell	3,456	$62.29	$215,274.24	36,958
1/4/2024	Sell	7,598	$55.27	$419,941.46	17,859
8/4/2023	Sell	3,000	$35.38	$106,140.00	7,795
7/3/2023	Sell	3,000	$31.75	$95,250.00	7,795
5/9/2023	Sell	500	$45.00	$22,500.00	9,992
5/5/2023	Sell	1,200	$45.00	$54,000.00	10,492
5/3/2023	Sell	3,000	$43.44	$130,320.00	11,692
4/24/2023	Sell	20,000	$40.00	$800,000.00	11,692
4/19/2023	Sell	15,642	$35.01	$547,626.42	11,692
4/3/2023	Sell	3,000	$30.71	$92,130.00	15,589
2/9/2023	Sell	6,966	$30.77	$214,343.82	15,589
2/3/2023	Sell	1,255	$35.11	$44,063.05
1/3/2023	Sell	2,500	$31.11	$77,775.00
12/13/2022	Sell	12,500	$30.03	$375,375.00

Christopher Heery Buying and Selling Activity at Arcellx

Arcellx Company Overview

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Today's Range

Now: $75.54

$73.40

$76.41

50 Day Range

MA: $88.59

$75.21

$106.53

2 Week Range

Now: $75.54

$47.88

$107.37

Volume

1,372,259 shs

Average Volume

491,145 shs

Market Capitalization

$4.08 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.25

Amazon coin set to soar 25X – starting December 16th?

From True Market Insiders | Ad

>3-Cent Amazon Coin<

Christopher Heery Biography and Net Worth

What is Christopher Heery's net worth?

How old is Christopher Heery?

What is Christopher Heery's salary?

How do I contact Christopher Heery?

Has Christopher Heery been buying or selling shares of Arcellx?

Who are Arcellx's active insiders?

Are insiders buying or selling shares of Arcellx?